NO314285B1 - Fremgangsmåte ved emulgering av uopplöselige eller dårlig opplöselige materialer samt suspensjon dannet ved fremgangsmåten, partikler oganvendelse - Google Patents

Info

Publication number

NO314285B1

NO314285B1 NO19953461A NO953461A NO314285B1 NO 314285 B1 NO314285 B1 NO 314285B1 NO 19953461 A NO19953461 A NO 19953461A NO 953461 A NO953461 A NO 953461A NO 314285 B1 NO314285 B1 NO 314285B1

Authority

NO

Norway

Prior art keywords

slp

particles

dispersion

agents

lipid

Prior art date

1993-03-05

Links

• Espacenet
• Global Dossier
• Discuss

• 239000002245 particle Substances 0.000 title claims abstract description 228
• 238000000034 method Methods 0.000 title claims abstract description 60
• 239000000725 suspension Substances 0.000 title claims abstract description 54
• 230000008569 process Effects 0.000 title claims abstract description 14
• 230000001804 emulsifying effect Effects 0.000 title claims description 3
• 239000002195 soluble material Substances 0.000 title claims 2
• 150000002632 lipids Chemical class 0.000 claims abstract description 107
• 239000003814 drug Substances 0.000 claims abstract description 82
• 229940079593 drug Drugs 0.000 claims abstract description 81
• 239000007787 solid Substances 0.000 claims abstract description 57
• 239000000126 substance Substances 0.000 claims abstract description 57
• 238000002360 preparation method Methods 0.000 claims abstract description 35
• 230000000975 bioactive effect Effects 0.000 claims abstract description 33
• 238000000265 homogenisation Methods 0.000 claims abstract description 32
• 239000000463 material Substances 0.000 claims abstract description 31
• 230000008018 melting Effects 0.000 claims abstract description 23
• 238000002844 melting Methods 0.000 claims abstract description 23
• 239000012867 bioactive agent Substances 0.000 claims abstract description 21
• 230000004048 modification Effects 0.000 claims abstract description 19
• 238000012986 modification Methods 0.000 claims abstract description 19
• 238000004945 emulsification Methods 0.000 claims abstract description 16
• 239000006185 dispersion Substances 0.000 claims description 193
• PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 132
• 238000009210 therapy by ultrasound Methods 0.000 claims description 61
• 239000000203 mixture Substances 0.000 claims description 53
• 239000003381 stabilizer Substances 0.000 claims description 47
• 238000004519 manufacturing process Methods 0.000 claims description 46
• 150000003904 phospholipids Chemical class 0.000 claims description 39
• 239000002612 dispersion medium Substances 0.000 claims description 31
• OABYVIYXWMZFFJ-ZUHYDKSRSA-M sodium glycocholate Chemical compound [Na+].C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 OABYVIYXWMZFFJ-ZUHYDKSRSA-M 0.000 claims description 31
• 150000001875 compounds Chemical class 0.000 claims description 27
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 27
• 239000004094 surface-active agent Substances 0.000 claims description 25
• 239000003833 bile salt Substances 0.000 claims description 24
• -1 rpilocaine Chemical compound 0.000 claims description 23
• 238000001953 recrystallisation Methods 0.000 claims description 22
• 238000001816 cooling Methods 0.000 claims description 21
• 239000000839 emulsion Substances 0.000 claims description 21
• 239000007788 liquid Substances 0.000 claims description 19
• MDYZKJNTKZIUSK-UHFFFAOYSA-N tyloxapol Chemical compound O=C.C1CO1.CC(C)(C)CC(C)(C)C1=CC=C(O)C=C1 MDYZKJNTKZIUSK-UHFFFAOYSA-N 0.000 claims description 19
• 229960004224 tyloxapol Drugs 0.000 claims description 19
• 229920001664 tyloxapol Polymers 0.000 claims description 19
• HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 claims description 18
• 229960001680 ibuprofen Drugs 0.000 claims description 18
• NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 claims description 17
• 239000003795 chemical substances by application Substances 0.000 claims description 16
• 150000002148 esters Chemical class 0.000 claims description 16
• 229960004194 lidocaine Drugs 0.000 claims description 16
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 15
• 229940093761 bile salts Drugs 0.000 claims description 15
• 239000000693 micelle Substances 0.000 claims description 15
• FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 claims description 14
• 238000004108 freeze drying Methods 0.000 claims description 14
• 210000001035 gastrointestinal tract Anatomy 0.000 claims description 14
• 229920000642 polymer Polymers 0.000 claims description 12
• 230000015572 biosynthetic process Effects 0.000 claims description 11
• 239000012071 phase Substances 0.000 claims description 11
• MJVAVZPDRWSRRC-UHFFFAOYSA-N Menadione Chemical compound C1=CC=C2C(=O)C(C)=CC(=O)C2=C1 MJVAVZPDRWSRRC-UHFFFAOYSA-N 0.000 claims description 10
• BYBLEWFAAKGYCD-UHFFFAOYSA-N Miconazole Chemical compound ClC1=CC(Cl)=CC=C1COC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 BYBLEWFAAKGYCD-UHFFFAOYSA-N 0.000 claims description 10
• 229960002509 miconazole Drugs 0.000 claims description 10
• FRPJXPJMRWBBIH-RBRWEJTLSA-N estramustine Chemical compound ClCCN(CCCl)C(=O)OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 FRPJXPJMRWBBIH-RBRWEJTLSA-N 0.000 claims description 9
• 229960001842 estramustine Drugs 0.000 claims description 9
• 150000002191 fatty alcohols Chemical class 0.000 claims description 9
• FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 claims description 8
• 238000001914 filtration Methods 0.000 claims description 8
• 239000004009 herbicide Substances 0.000 claims description 8
• 239000000575 pesticide Substances 0.000 claims description 8
• 150000003626 triacylglycerols Chemical class 0.000 claims description 8
• 239000001993 wax Substances 0.000 claims description 8
• FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 claims description 7
• MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 claims description 7
• MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 claims description 7
• QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims description 7
• 229960004544 cortisone Drugs 0.000 claims description 7
• 239000013078 crystal Substances 0.000 claims description 7
• 235000014113 dietary fatty acids Nutrition 0.000 claims description 7
• 150000002170 ethers Chemical class 0.000 claims description 7
• 229930195729 fatty acid Natural products 0.000 claims description 7
• 239000000194 fatty acid Substances 0.000 claims description 7
• 150000004665 fatty acids Chemical class 0.000 claims description 7
• 239000002917 insecticide Substances 0.000 claims description 7
• 239000011343 solid material Substances 0.000 claims description 7
• 239000011647 vitamin D3 Substances 0.000 claims description 7
• 235000005282 vitamin D3 Nutrition 0.000 claims description 7
• QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 claims description 7
• 229940021056 vitamin d3 Drugs 0.000 claims description 7
• VYGQUTWHTHXGQB-FFHKNEKCSA-N Retinol Palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C VYGQUTWHTHXGQB-FFHKNEKCSA-N 0.000 claims description 6
• MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 claims description 6
• 238000010521 absorption reaction Methods 0.000 claims description 6
• 239000000654 additive Substances 0.000 claims description 6
• YKPUWZUDDOIDPM-SOFGYWHQSA-N capsaicin Chemical compound COC1=CC(CNC(=O)CCCC\C=C\C(C)C)=CC=C1O YKPUWZUDDOIDPM-SOFGYWHQSA-N 0.000 claims description 6
• 239000002577 cryoprotective agent Substances 0.000 claims description 6
• 239000007951 isotonicity adjuster Substances 0.000 claims description 6
• 239000012768 molten material Substances 0.000 claims description 6
• SATCULPHIDQDRE-UHFFFAOYSA-N piperonal Chemical compound O=CC1=CC=C2OCOC2=C1 SATCULPHIDQDRE-UHFFFAOYSA-N 0.000 claims description 6
• NBFQYHKHPBMJJV-UHFFFAOYSA-N risocaine Chemical compound CCCOC(=O)C1=CC=C(N)C=C1 NBFQYHKHPBMJJV-UHFFFAOYSA-N 0.000 claims description 6
• CEMAWMOMDPGJMB-UHFFFAOYSA-N (+-)-Oxprenolol Chemical compound CC(C)NCC(O)COC1=CC=CC=C1OCC=C CEMAWMOMDPGJMB-UHFFFAOYSA-N 0.000 claims description 5
• 229930012538 Paclitaxel Natural products 0.000 claims description 5
• 150000001298 alcohols Chemical class 0.000 claims description 5
• 229940124630 bronchodilator Drugs 0.000 claims description 5
• 239000000168 bronchodilator agent Substances 0.000 claims description 5
• JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 claims description 5
• 229960004630 chlorambucil Drugs 0.000 claims description 5
• 239000000824 cytostatic agent Substances 0.000 claims description 5
• 230000001085 cytostatic effect Effects 0.000 claims description 5
• AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 claims description 5
• 229960003529 diazepam Drugs 0.000 claims description 5
• ADIMAYPTOBDMTL-UHFFFAOYSA-N oxazepam Chemical compound C12=CC(Cl)=CC=C2NC(=O)C(O)N=C1C1=CC=CC=C1 ADIMAYPTOBDMTL-UHFFFAOYSA-N 0.000 claims description 5
• 229960004535 oxazepam Drugs 0.000 claims description 5
• 229960004570 oxprenolol Drugs 0.000 claims description 5
• 229960001592 paclitaxel Drugs 0.000 claims description 5
• 229960005205 prednisolone Drugs 0.000 claims description 5
• OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 claims description 5
• 239000003755 preservative agent Substances 0.000 claims description 5
• 229960003471 retinol Drugs 0.000 claims description 5
• 235000020944 retinol Nutrition 0.000 claims description 5
• 239000011607 retinol Substances 0.000 claims description 5
• RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims description 5
• 235000012711 vitamin K3 Nutrition 0.000 claims description 5
• 239000011652 vitamin K3 Substances 0.000 claims description 5
• OMDMTHRBGUBUCO-IUCAKERBSA-N (1s,5s)-5-(2-hydroxypropan-2-yl)-2-methylcyclohex-2-en-1-ol Chemical compound CC1=CC[C@H](C(C)(C)O)C[C@@H]1O OMDMTHRBGUBUCO-IUCAKERBSA-N 0.000 claims description 4
• AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims description 4
• RPTUSVTUFVMDQK-UHFFFAOYSA-N Hidralazin Chemical compound C1=CC=C2C(NN)=NN=CC2=C1 RPTUSVTUFVMDQK-UHFFFAOYSA-N 0.000 claims description 4
• NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 claims description 4
• RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 claims description 4
• CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 4
• 229930006000 Sucrose Natural products 0.000 claims description 4
• 229940035674 anesthetics Drugs 0.000 claims description 4
• 229940121375 antifungal agent Drugs 0.000 claims description 4
• 239000003429 antifungal agent Substances 0.000 claims description 4
• 239000003443 antiviral agent Substances 0.000 claims description 4
• 239000000872 buffer Substances 0.000 claims description 4
• HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 4
• 239000000356 contaminant Substances 0.000 claims description 4
• ADYPXRFPBQGGAH-WVVAGBSPSA-N dihydroergotoxine Chemical compound CS(O)(=O)=O.C([C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@@](C(N21)=O)(C)NC(=O)[C@H]1CN([C@H]2C(C=3C=CC=C4NC=C(C=34)C2)C1)C)C1=CC=CC=C1 ADYPXRFPBQGGAH-WVVAGBSPSA-N 0.000 claims description 4
• 229940120500 dihydroergotoxine Drugs 0.000 claims description 4
• 230000002255 enzymatic effect Effects 0.000 claims description 4
• 239000003193 general anesthetic agent Substances 0.000 claims description 4
• 238000009775 high-speed stirring Methods 0.000 claims description 4
• JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 claims description 4
• CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 claims description 4
• 239000002563 ionic surfactant Substances 0.000 claims description 4
• 239000004081 narcotic agent Substances 0.000 claims description 4
• 239000002736 nonionic surfactant Substances 0.000 claims description 4
• 238000001556 precipitation Methods 0.000 claims description 4
• 108090000765 processed proteins & peptides Proteins 0.000 claims description 4
• AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 claims description 4
• 239000005720 sucrose Substances 0.000 claims description 4
• 235000000346 sugar Nutrition 0.000 claims description 4
• 150000005846 sugar alcohols Chemical class 0.000 claims description 4
• 238000000108 ultra-filtration Methods 0.000 claims description 4
• 229940124549 vasodilator Drugs 0.000 claims description 4
• 239000003071 vasodilator agent Substances 0.000 claims description 4
• RXPRRQLKFXBCSJ-GIVPXCGWSA-N vincamine Chemical compound C1=CC=C2C(CCN3CCC4)=C5[C@@H]3[C@]4(CC)C[C@](O)(C(=O)OC)N5C2=C1 RXPRRQLKFXBCSJ-GIVPXCGWSA-N 0.000 claims description 4
• 235000019155 vitamin A Nutrition 0.000 claims description 4
• 239000011719 vitamin A Substances 0.000 claims description 4
• HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims description 3
• CXBMCYHAMVGWJQ-CABCVRRESA-N (1,3-dioxo-4,5,6,7-tetrahydroisoindol-2-yl)methyl (1r,3r)-2,2-dimethyl-3-(2-methylprop-1-enyl)cyclopropane-1-carboxylate Chemical compound CC1(C)[C@H](C=C(C)C)[C@H]1C(=O)OCN1C(=O)C(CCCC2)=C2C1=O CXBMCYHAMVGWJQ-CABCVRRESA-N 0.000 claims description 3
• APUDBKTWDCXQJA-XQBPLPMBSA-N (1R)-4-[(2S,6R)-2,6-dimethylpiperidin-1-yl]-1-phenyl-1-pyridin-2-ylbutan-1-ol Chemical compound C[C@H]1CCC[C@@H](C)N1CCC[C@](O)(C=1N=CC=CC=1)C1=CC=CC=C1 APUDBKTWDCXQJA-XQBPLPMBSA-N 0.000 claims description 3
• NXQMNKUGGYNLBY-GFCCVEGCSA-N (2r)-1-(3-methylphenoxy)-3-(propan-2-ylamino)propan-2-ol Chemical compound CC(C)NC[C@@H](O)COC1=CC=CC(C)=C1 NXQMNKUGGYNLBY-GFCCVEGCSA-N 0.000 claims description 3
• MXOAEAUPQDYUQM-QMMMGPOBSA-N (S)-chlorphenesin Chemical compound OC[C@H](O)COC1=CC=C(Cl)C=C1 MXOAEAUPQDYUQM-QMMMGPOBSA-N 0.000 claims description 3
• PUYOAVGNCWPANW-UHFFFAOYSA-N 2-methylpropyl 4-aminobenzoate Chemical compound CC(C)COC(=O)C1=CC=C(N)C=C1 PUYOAVGNCWPANW-UHFFFAOYSA-N 0.000 claims description 3
• XQJMXPAEFMWDOZ-UHFFFAOYSA-N 3exo-benzoyloxy-tropane Natural products CN1C(C2)CCC1CC2OC(=O)C1=CC=CC=C1 XQJMXPAEFMWDOZ-UHFFFAOYSA-N 0.000 claims description 3
• JYJFNDQBESEHJQ-UHFFFAOYSA-N 5,5-dimethyloxazolidine-2,4-dione Chemical compound CC1(C)OC(=O)NC1=O JYJFNDQBESEHJQ-UHFFFAOYSA-N 0.000 claims description 3
• MXUNKHLAEDCYJL-UHFFFAOYSA-N 5-(hydroxymethyl)-3-(3-methylphenyl)-1,3-oxazolidin-2-one Chemical compound CC1=CC=CC(N2C(OC(CO)C2)=O)=C1 MXUNKHLAEDCYJL-UHFFFAOYSA-N 0.000 claims description 3
• JWBOIMRXGHLCPP-UHFFFAOYSA-N Chloditan Chemical compound C=1C=CC=C(Cl)C=1C(C(Cl)Cl)C1=CC=C(Cl)C=C1 JWBOIMRXGHLCPP-UHFFFAOYSA-N 0.000 claims description 3
• 239000005946 Cypermethrin Substances 0.000 claims description 3
• IELOKBJPULMYRW-NJQVLOCASA-N D-alpha-Tocopheryl Acid Succinate Chemical compound OC(=O)CCC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C IELOKBJPULMYRW-NJQVLOCASA-N 0.000 claims description 3
• ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 claims description 3
• SPKNARKFCOPTSY-UHFFFAOYSA-N D-asperlin Natural products CC1OC1C1C(OC(C)=O)C=CC(=O)O1 SPKNARKFCOPTSY-UHFFFAOYSA-N 0.000 claims description 3
• WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 3
• 241001465754 Metazoa Species 0.000 claims description 3
• DUGOZIWVEXMGBE-UHFFFAOYSA-N Methylphenidate Chemical compound C=1C=CC=CC=1C(C(=O)OC)C1CCCCN1 DUGOZIWVEXMGBE-UHFFFAOYSA-N 0.000 claims description 3
• IFFPICMESYHZPQ-UHFFFAOYSA-N Prenylamine Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)CCNC(C)CC1=CC=CC=C1 IFFPICMESYHZPQ-UHFFFAOYSA-N 0.000 claims description 3
• JLRNKCZRCMIVKA-UHFFFAOYSA-N Simfibrate Chemical compound C=1C=C(Cl)C=CC=1OC(C)(C)C(=O)OCCCOC(=O)C(C)(C)OC1=CC=C(Cl)C=C1 JLRNKCZRCMIVKA-UHFFFAOYSA-N 0.000 claims description 3
• DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims description 3
• 229930182558 Sterol Natural products 0.000 claims description 3
• KLBQZWRITKRQQV-UHFFFAOYSA-N Thioridazine Chemical compound C12=CC(SC)=CC=C2SC2=CC=CC=C2N1CCC1CCCCN1C KLBQZWRITKRQQV-UHFFFAOYSA-N 0.000 claims description 3
• MSCCTZZBYHQMQJ-AZAGJHQNSA-N Tocopheryl nicotinate Chemical compound C([C@@](OC1=C(C)C=2C)(C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)CC1=C(C)C=2OC(=O)C1=CC=CN=C1 MSCCTZZBYHQMQJ-AZAGJHQNSA-N 0.000 claims description 3
• HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims description 3
• TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims description 3
• SPKNARKFCOPTSY-XWPZMVOTSA-N [(2r,3s)-2-[(2s,3r)-3-methyloxiran-2-yl]-6-oxo-2,3-dihydropyran-3-yl] acetate Chemical compound C[C@H]1O[C@@H]1[C@H]1[C@@H](OC(C)=O)C=CC(=O)O1 SPKNARKFCOPTSY-XWPZMVOTSA-N 0.000 claims description 3
• YASYVMFAVPKPKE-UHFFFAOYSA-N acephate Chemical compound COP(=O)(SC)NC(C)=O YASYVMFAVPKPKE-UHFFFAOYSA-N 0.000 claims description 3
• 239000002671 adjuvant Substances 0.000 claims description 3
• 150000004347 all-trans-retinol derivatives Chemical class 0.000 claims description 3
• HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims description 3
• PAZJSJFMUHDSTF-UHFFFAOYSA-N alprenolol Chemical compound CC(C)NCC(O)COC1=CC=CC=C1CC=C PAZJSJFMUHDSTF-UHFFFAOYSA-N 0.000 claims description 3
• 229960002213 alprenolol Drugs 0.000 claims description 3
• 150000001413 amino acids Chemical class 0.000 claims description 3
• YZQNFFLGIYEXMM-UHFFFAOYSA-N aminopromazine Chemical compound C1=CC=C2N(CC(CN(C)C)N(C)C)C3=CC=CC=C3SC2=C1 YZQNFFLGIYEXMM-UHFFFAOYSA-N 0.000 claims description 3
• 229950005325 aminopromazine Drugs 0.000 claims description 3
• 239000002260 anti-inflammatory agent Substances 0.000 claims description 3
• 239000001961 anticonvulsive agent Substances 0.000 claims description 3
• 239000000935 antidepressant agent Substances 0.000 claims description 3
• 229940005513 antidepressants Drugs 0.000 claims description 3
• 239000003524 antilipemic agent Substances 0.000 claims description 3
• XTKDAFGWCDAMPY-UHFFFAOYSA-N azaperone Chemical compound C1=CC(F)=CC=C1C(=O)CCCN1CCN(C=2N=CC=CC=2)CC1 XTKDAFGWCDAMPY-UHFFFAOYSA-N 0.000 claims description 3
• 229950003616 azaperone Drugs 0.000 claims description 3
• VVUYEFBRTFASAH-UHFFFAOYSA-N bamifylline Chemical compound N=1C=2N(C)C(=O)N(C)C(=O)C=2N(CCN(CCO)CC)C=1CC1=CC=CC=C1 VVUYEFBRTFASAH-UHFFFAOYSA-N 0.000 claims description 3
• 229960005176 bamifylline Drugs 0.000 claims description 3
• 235000013871 bee wax Nutrition 0.000 claims description 3
• 239000012166 beeswax Substances 0.000 claims description 3
• WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 3
• 229920001400 block copolymer Polymers 0.000 claims description 3
• YFLRYAVDPKONNX-UHFFFAOYSA-N buramate Chemical compound OCCOC(=O)NCC1=CC=CC=C1 YFLRYAVDPKONNX-UHFFFAOYSA-N 0.000 claims description 3
• 229950009824 buramate Drugs 0.000 claims description 3
• 229960002973 butibufen Drugs 0.000 claims description 3
• UULSXYSSHHRCQK-UHFFFAOYSA-N butibufen Chemical compound CCC(C(O)=O)C1=CC=C(CC(C)C)C=C1 UULSXYSSHHRCQK-UHFFFAOYSA-N 0.000 claims description 3
• 229950001141 butobendine Drugs 0.000 claims description 3
• ZKSIPEYIAHUPNM-ZEQRLZLVSA-N butobendine Chemical compound C([C@H](CC)N(C)CCN(C)[C@@H](CC)COC(=O)C=1C=C(OC)C(OC)=C(OC)C=1)OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 ZKSIPEYIAHUPNM-ZEQRLZLVSA-N 0.000 claims description 3
• SWLMUYACZKCSHZ-UHFFFAOYSA-N butoconazole Chemical compound C1=CC(Cl)=CC=C1CCC(SC=1C(=CC=CC=1Cl)Cl)CN1C=NC=C1 SWLMUYACZKCSHZ-UHFFFAOYSA-N 0.000 claims description 3
• 229960005074 butoconazole Drugs 0.000 claims description 3
• 229960002504 capsaicin Drugs 0.000 claims description 3
• 235000017663 capsaicin Nutrition 0.000 claims description 3
• 239000002327 cardiovascular agent Substances 0.000 claims description 3
• 229940125692 cardiovascular agent Drugs 0.000 claims description 3
• 239000004203 carnauba wax Substances 0.000 claims description 3
• 235000013869 carnauba wax Nutrition 0.000 claims description 3
• 229960003993 chlorphenesin Drugs 0.000 claims description 3
• ZPEIMTDSQAKGNT-UHFFFAOYSA-N chlorpromazine Chemical compound C1=C(Cl)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 ZPEIMTDSQAKGNT-UHFFFAOYSA-N 0.000 claims description 3
• 229960001076 chlorpromazine Drugs 0.000 claims description 3
• 229960001591 cyfluthrin Drugs 0.000 claims description 3
• QQODLKZGRKWIFG-QSFXBCCZSA-N cyfluthrin Chemical compound CC1(C)[C@@H](C=C(Cl)Cl)[C@H]1C(=O)O[C@@H](C#N)C1=CC=C(F)C(OC=2C=CC=CC=2)=C1 QQODLKZGRKWIFG-QSFXBCCZSA-N 0.000 claims description 3
• 229960005424 cypermethrin Drugs 0.000 claims description 3
• KAATUXNTWXVJKI-UHFFFAOYSA-N cypermethrin Chemical compound CC1(C)C(C=C(Cl)Cl)C1C(=O)OC(C#N)C1=CC=CC(OC=2C=CC=CC=2)=C1 KAATUXNTWXVJKI-UHFFFAOYSA-N 0.000 claims description 3
• 229940099418 d- alpha-tocopherol succinate Drugs 0.000 claims description 3
• LWJWGXUXSVJWBY-UHFFFAOYSA-N dihydroxy-phenoxy-sulfanylidene-$l^{5}-phosphane Chemical class OP(O)(=S)OC1=CC=CC=C1 LWJWGXUXSVJWBY-UHFFFAOYSA-N 0.000 claims description 3
• 229950004446 dimethadione Drugs 0.000 claims description 3
• 239000003792 electrolyte Substances 0.000 claims description 3
• NPUKDXXFDDZOKR-LLVKDONJSA-N etomidate Chemical compound CCOC(=O)C1=CN=CN1[C@H](C)C1=CC=CC=C1 NPUKDXXFDDZOKR-LLVKDONJSA-N 0.000 claims description 3
• 229960001690 etomidate Drugs 0.000 claims description 3
• CKSJXOVLXUMMFF-UHFFFAOYSA-N exalamide Chemical compound CCCCCCOC1=CC=CC=C1C(N)=O CKSJXOVLXUMMFF-UHFFFAOYSA-N 0.000 claims description 3
• 229950010333 exalamide Drugs 0.000 claims description 3
• 229950010338 fencarbamide Drugs 0.000 claims description 3
• CVHGCWVMTZWGAY-UHFFFAOYSA-N fomocaine Chemical compound C=1C=C(COC=2C=CC=CC=2)C=CC=1CCCN1CCOCC1 CVHGCWVMTZWGAY-UHFFFAOYSA-N 0.000 claims description 3
• 229950003051 fomocaine Drugs 0.000 claims description 3
• 239000008103 glucose Substances 0.000 claims description 3
• 239000008172 hydrogenated vegetable oil Substances 0.000 claims description 3
• 230000000544 hyperemic effect Effects 0.000 claims description 3
• 229950008706 isobutamben Drugs 0.000 claims description 3
• 239000007791 liquid phase Substances 0.000 claims description 3
• 150000004668 long chain fatty acids Chemical class 0.000 claims description 3
• HHRZAEJMHSGZNP-UHFFFAOYSA-N mebanazine Chemical compound NNC(C)C1=CC=CC=C1 HHRZAEJMHSGZNP-UHFFFAOYSA-N 0.000 claims description 3
• HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims description 3
• ZPUCINDJVBIVPJ-XGUBFFRZSA-N methyl (1s,3s,4s,5r)-3-benzoyloxy-8-methyl-8-azabicyclo[3.2.1]octane-4-carboxylate Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-XGUBFFRZSA-N 0.000 claims description 3
• 229960001344 methylphenidate Drugs 0.000 claims description 3
• MJFJKKXQDNNUJF-UHFFFAOYSA-N metixene Chemical compound C1N(C)CCCC1CC1C2=CC=CC=C2SC2=CC=CC=C21 MJFJKKXQDNNUJF-UHFFFAOYSA-N 0.000 claims description 3
• 229960005103 metixene Drugs 0.000 claims description 3
• 229960000350 mitotane Drugs 0.000 claims description 3
• 229950011138 nicoclonate Drugs 0.000 claims description 3
• XPPXHQUWVYMTDM-UHFFFAOYSA-N nicoclonate Chemical compound C=1C=C(Cl)C=CC=1C(C(C)C)OC(=O)C1=CC=CN=C1 XPPXHQUWVYMTDM-UHFFFAOYSA-N 0.000 claims description 3
• RARQHAFNGNPQCZ-UHFFFAOYSA-N nicofibrate Chemical compound C=1C=CN=CC=1COC(=O)C(C)(C)OC1=CC=C(Cl)C=C1 RARQHAFNGNPQCZ-UHFFFAOYSA-N 0.000 claims description 3
• 229950005171 nicofibrate Drugs 0.000 claims description 3
• NCYVXEGFNDZQCU-UHFFFAOYSA-N nikethamide Chemical compound CCN(CC)C(=O)C1=CC=CN=C1 NCYVXEGFNDZQCU-UHFFFAOYSA-N 0.000 claims description 3
• 229960003226 nikethamide Drugs 0.000 claims description 3
• WEYVCQFUGFRXOM-UHFFFAOYSA-N perazine Chemical compound C1CN(C)CCN1CCCN1C2=CC=CC=C2SC2=CC=CC=C21 WEYVCQFUGFRXOM-UHFFFAOYSA-N 0.000 claims description 3
• 229960002195 perazine Drugs 0.000 claims description 3
• 229940081310 piperonal Drugs 0.000 claims description 3
• 229950000957 pirifibrate Drugs 0.000 claims description 3
• YJBIJSVYPHRVCI-UHFFFAOYSA-N pirifibrate Chemical compound C=1C=CC(CO)=NC=1COC(=O)C(C)(C)OC1=CC=C(Cl)C=C1 YJBIJSVYPHRVCI-UHFFFAOYSA-N 0.000 claims description 3
• 229950008066 pirmenol Drugs 0.000 claims description 3
• 229920001184 polypeptide Polymers 0.000 claims description 3
• 239000011148 porous material Substances 0.000 claims description 3
• 229960001989 prenylamine Drugs 0.000 claims description 3
• REQCZEXYDRLIBE-UHFFFAOYSA-N procainamide Chemical compound CCN(CC)CCNC(=O)C1=CC=C(N)C=C1 REQCZEXYDRLIBE-UHFFFAOYSA-N 0.000 claims description 3
• 229960000244 procainamide Drugs 0.000 claims description 3
• 102000004196 processed proteins & peptides Human genes 0.000 claims description 3
• CDOZDBSBBXSXLB-UHFFFAOYSA-N profenamine Chemical compound C1=CC=C2N(CC(C)N(CC)CC)C3=CC=CC=C3SC2=C1 CDOZDBSBBXSXLB-UHFFFAOYSA-N 0.000 claims description 3
• 108090000623 proteins and genes Proteins 0.000 claims description 3
• 102000004169 proteins and genes Human genes 0.000 claims description 3
• 239000003368 psychostimulant agent Substances 0.000 claims description 3
• 229960000342 retinol acetate Drugs 0.000 claims description 3
• QGNJRVVDBSJHIZ-QHLGVNSISA-N retinyl acetate Chemical compound CC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C QGNJRVVDBSJHIZ-QHLGVNSISA-N 0.000 claims description 3
• 235000019173 retinyl acetate Nutrition 0.000 claims description 3
• 239000011770 retinyl acetate Substances 0.000 claims description 3
• 229940108325 retinyl palmitate Drugs 0.000 claims description 3
• 235000019172 retinyl palmitate Nutrition 0.000 claims description 3
• 239000011769 retinyl palmitate Substances 0.000 claims description 3
• 229950003447 risocaine Drugs 0.000 claims description 3
• BZGIPVGCJGXQTA-UHFFFAOYSA-N s-[2-(diethylamino)ethyl] n,n-diphenylcarbamothioate Chemical compound C=1C=CC=CC=1N(C(=O)SCCN(CC)CC)C1=CC=CC=C1 BZGIPVGCJGXQTA-UHFFFAOYSA-N 0.000 claims description 3
• 229960004058 simfibrate Drugs 0.000 claims description 3
• 239000001509 sodium citrate Substances 0.000 claims description 3
• NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 claims description 3
• FQENQNTWSFEDLI-UHFFFAOYSA-J sodium diphosphate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]P([O-])(=O)OP([O-])([O-])=O FQENQNTWSFEDLI-UHFFFAOYSA-J 0.000 claims description 3
• 229940048086 sodium pyrophosphate Drugs 0.000 claims description 3
• 230000002048 spasmolytic effect Effects 0.000 claims description 3
• 150000003432 sterols Chemical class 0.000 claims description 3
• 235000003702 sterols Nutrition 0.000 claims description 3
• 229960003484 testosterone enanthate Drugs 0.000 claims description 3
• VOCBWIIFXDYGNZ-IXKNJLPQSA-N testosterone enanthate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](OC(=O)CCCCCC)[C@@]1(C)CC2 VOCBWIIFXDYGNZ-IXKNJLPQSA-N 0.000 claims description 3
• 150000003515 testosterones Chemical class 0.000 claims description 3
• GKCBAIGFKIBETG-UHFFFAOYSA-N tetracaine Chemical compound CCCCNC1=CC=C(C(=O)OCCN(C)C)C=C1 GKCBAIGFKIBETG-UHFFFAOYSA-N 0.000 claims description 3
• 229960002372 tetracaine Drugs 0.000 claims description 3
• 229960005199 tetramethrin Drugs 0.000 claims description 3
• 235000019818 tetrasodium diphosphate Nutrition 0.000 claims description 3
• 239000001577 tetrasodium phosphonato phosphate Substances 0.000 claims description 3
• 229960002784 thioridazine Drugs 0.000 claims description 3
• 229960000822 tiadenol Drugs 0.000 claims description 3
• WRCITXQNXAIKLR-UHFFFAOYSA-N tiadenol Chemical compound OCCSCCCCCCCCCCSCCO WRCITXQNXAIKLR-UHFFFAOYSA-N 0.000 claims description 3
• FDBWMYOFXWMGEY-UHFFFAOYSA-N tiropramide Chemical compound C=1C=CC=CC=1C(=O)NC(C(=O)N(CCC)CCC)CC1=CC=C(OCCN(CC)CC)C=C1 FDBWMYOFXWMGEY-UHFFFAOYSA-N 0.000 claims description 3
• 229960001899 tiropramide Drugs 0.000 claims description 3
• 229940042585 tocopherol acetate Drugs 0.000 claims description 3
• 229950009883 tocopheryl nicotinate Drugs 0.000 claims description 3
• 229950000245 toliprolol Drugs 0.000 claims description 3
• 229960002309 toloxatone Drugs 0.000 claims description 3
• ZSDSQXJSNMTJDA-UHFFFAOYSA-N trifluralin Chemical compound CCCN(CCC)C1=C([N+]([O-])=O)C=C(C(F)(F)F)C=C1[N+]([O-])=O ZSDSQXJSNMTJDA-UHFFFAOYSA-N 0.000 claims description 3
• GOZBHBFUQHMKQB-UHFFFAOYSA-N trimecaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=C(C)C=C1C GOZBHBFUQHMKQB-UHFFFAOYSA-N 0.000 claims description 3
• 229950002569 trimecaine Drugs 0.000 claims description 3
• 229960000875 trofosfamide Drugs 0.000 claims description 3
• UMKFEPPTGMDVMI-UHFFFAOYSA-N trofosfamide Chemical compound ClCCN(CCCl)P1(=O)OCCCN1CCCl UMKFEPPTGMDVMI-UHFFFAOYSA-N 0.000 claims description 3
• XQJMXPAEFMWDOZ-BTTYYORXSA-N tropacocaine Chemical compound O([C@@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C1=CC=CC=C1 XQJMXPAEFMWDOZ-BTTYYORXSA-N 0.000 claims description 3
• 150000004670 unsaturated fatty acids Chemical class 0.000 claims description 3
• 235000021122 unsaturated fatty acids Nutrition 0.000 claims description 3
• 150000003712 vitamin E derivatives Chemical class 0.000 claims description 3
• 239000000811 xylitol Substances 0.000 claims description 3
• HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims description 3
• 229960002675 xylitol Drugs 0.000 claims description 3
• 235000010447 xylitol Nutrition 0.000 claims description 3
• BFCDFTHTSVTWOG-YLJYHZDGSA-N (1S,2R)-2-(octylamino)-1-[4-(propan-2-ylthio)phenyl]-1-propanol Chemical compound CCCCCCCCN[C@H](C)[C@@H](O)C1=CC=C(SC(C)C)C=C1 BFCDFTHTSVTWOG-YLJYHZDGSA-N 0.000 claims description 2
• XMAYWYJOQHXEEK-OZXSUGGESA-N (2R,4S)-ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 claims description 2
• JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical class OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 claims description 2
• DIWRORZWFLOCLC-HNNXBMFYSA-N (3s)-7-chloro-5-(2-chlorophenyl)-3-hydroxy-1,3-dihydro-1,4-benzodiazepin-2-one Chemical compound N([C@H](C(NC1=CC=C(Cl)C=C11)=O)O)=C1C1=CC=CC=C1Cl DIWRORZWFLOCLC-HNNXBMFYSA-N 0.000 claims description 2
• METKIMKYRPQLGS-GFCCVEGCSA-N (R)-atenolol Chemical compound CC(C)NC[C@@H](O)COC1=CC=C(CC(N)=O)C=C1 METKIMKYRPQLGS-GFCCVEGCSA-N 0.000 claims description 2
• PVHUJELLJLJGLN-INIZCTEOSA-N (S)-nitrendipine Chemical compound CCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)[C@@H]1C1=CC=CC([N+]([O-])=O)=C1 PVHUJELLJLJGLN-INIZCTEOSA-N 0.000 claims description 2
• SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 claims description 2
• SGUAFYQXFOLMHL-UHFFFAOYSA-N 2-hydroxy-5-{1-hydroxy-2-[(4-phenylbutan-2-yl)amino]ethyl}benzamide Chemical compound C=1C=C(O)C(C(N)=O)=CC=1C(O)CNC(C)CCC1=CC=CC=C1 SGUAFYQXFOLMHL-UHFFFAOYSA-N 0.000 claims description 2
• UIAGMCDKSXEBJQ-IBGZPJMESA-N 3-o-(2-methoxyethyl) 5-o-propan-2-yl (4s)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound COCCOC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)[C@H]1C1=CC=CC([N+]([O-])=O)=C1 UIAGMCDKSXEBJQ-IBGZPJMESA-N 0.000 claims description 2
• AURFZBICLPNKBZ-YZRLXODZSA-N 3alpha-hydroxy-5beta-pregnan-20-one Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](C(=O)C)[C@@]2(C)CC1 AURFZBICLPNKBZ-YZRLXODZSA-N 0.000 claims description 2
• 239000005541 ACE inhibitor Substances 0.000 claims description 2
• 102000009027 Albumins Human genes 0.000 claims description 2
• 108010088751 Albumins Proteins 0.000 claims description 2
• 108010006654 Bleomycin Proteins 0.000 claims description 2
• VMIYHDSEFNYJSL-UHFFFAOYSA-N Bromazepam Chemical compound C12=CC(Br)=CC=C2NC(=O)CN=C1C1=CC=CC=N1 VMIYHDSEFNYJSL-UHFFFAOYSA-N 0.000 claims description 2
• 229940127291 Calcium channel antagonist Drugs 0.000 claims description 2
• 229930186147 Cephalosporin Natural products 0.000 claims description 2
• XCDXSSFOJZZGQC-UHFFFAOYSA-N Chlornaphazine Chemical compound C1=CC=CC2=CC(N(CCCl)CCCl)=CC=C21 XCDXSSFOJZZGQC-UHFFFAOYSA-N 0.000 claims description 2
• CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims description 2
• UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 claims description 2
• LTMHDMANZUZIPE-AMTYYWEZSA-N Digoxin Natural products O([C@H]1[C@H](C)O[C@H](O[C@@H]2C[C@@H]3[C@@](C)([C@@H]4[C@H]([C@]5(O)[C@](C)([C@H](O)C4)[C@H](C4=CC(=O)OC4)CC5)CC3)CC2)C[C@@H]1O)[C@H]1O[C@H](C)[C@@H](O[C@H]2O[C@@H](C)[C@H](O)[C@@H](O)C2)[C@@H](O)C1 LTMHDMANZUZIPE-AMTYYWEZSA-N 0.000 claims description 2
• IIUZTXTZRGLYTI-UHFFFAOYSA-N Dihydrogriseofulvin Natural products COC1CC(=O)CC(C)C11C(=O)C(C(OC)=CC(OC)=C2Cl)=C2O1 IIUZTXTZRGLYTI-UHFFFAOYSA-N 0.000 claims description 2
• 108010061435 Enalapril Proteins 0.000 claims description 2
• 108010010803 Gelatin Proteins 0.000 claims description 2
• UXWOXTQWVMFRSE-UHFFFAOYSA-N Griseoviridin Natural products O=C1OC(C)CC=C(C(NCC=CC=CC(O)CC(O)C2)=O)SCC1NC(=O)C1=COC2=N1 UXWOXTQWVMFRSE-UHFFFAOYSA-N 0.000 claims description 2
• 108060003951 Immunoglobulin Proteins 0.000 claims description 2
• NTIZESTWPVYFNL-UHFFFAOYSA-N Methyl isobutyl ketone Chemical compound CC(C)CC(C)=O NTIZESTWPVYFNL-UHFFFAOYSA-N 0.000 claims description 2
• UIHCLUNTQKBZGK-UHFFFAOYSA-N Methyl isobutyl ketone Natural products CCC(C)C(C)=O UIHCLUNTQKBZGK-UHFFFAOYSA-N 0.000 claims description 2
• ZFMITUMMTDLWHR-UHFFFAOYSA-N Minoxidil Chemical compound NC1=[N+]([O-])C(N)=CC(N2CCCCC2)=N1 ZFMITUMMTDLWHR-UHFFFAOYSA-N 0.000 claims description 2
• DDUHZTYCFQRHIY-UHFFFAOYSA-N Negwer: 6874 Natural products COC1=CC(=O)CC(C)C11C(=O)C(C(OC)=CC(OC)=C2Cl)=C2O1 DDUHZTYCFQRHIY-UHFFFAOYSA-N 0.000 claims description 2
• 229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 2
• 239000004721 Polyphenylene oxide Substances 0.000 claims description 2
• AURFZBICLPNKBZ-UHFFFAOYSA-N Pregnanolone Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(=O)C)C1(C)CC2 AURFZBICLPNKBZ-UHFFFAOYSA-N 0.000 claims description 2
• 229920001963 Synthetic biodegradable polymer Polymers 0.000 claims description 2
• OIRDTQYFTABQOQ-UHTZMRCNSA-N Vidarabine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O OIRDTQYFTABQOQ-UHTZMRCNSA-N 0.000 claims description 2
• 229960004150 aciclovir Drugs 0.000 claims description 2
• MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 claims description 2
• 125000002877 alkyl aryl group Chemical group 0.000 claims description 2
• 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 claims description 2
• 239000003242 anti bacterial agent Substances 0.000 claims description 2
• 230000001741 anti-phlogistic effect Effects 0.000 claims description 2
• 229940088710 antibiotic agent Drugs 0.000 claims description 2
• 229940065524 anticholinergics inhalants for obstructive airway diseases Drugs 0.000 claims description 2
• 229940030600 antihypertensive agent Drugs 0.000 claims description 2
• 239000002220 antihypertensive agent Substances 0.000 claims description 2
• 229940124572 antihypotensive agent Drugs 0.000 claims description 2
• 229940121357 antivirals Drugs 0.000 claims description 2
• DIXRMZGIJNJUGL-UHFFFAOYSA-N arildone Chemical compound CCC(=O)C(C(=O)CC)CCCCCCOC1=CC=C(OC)C=C1Cl DIXRMZGIJNJUGL-UHFFFAOYSA-N 0.000 claims description 2
• 229950003470 arildone Drugs 0.000 claims description 2
• 229960002274 atenolol Drugs 0.000 claims description 2
• 239000002876 beta blocker Substances 0.000 claims description 2
• 229940097320 beta blocking agent Drugs 0.000 claims description 2
• 229960001561 bleomycin Drugs 0.000 claims description 2
• OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 claims description 2
• 229960002729 bromazepam Drugs 0.000 claims description 2
• 229960000830 captopril Drugs 0.000 claims description 2
• FAKRSMQSSFJEIM-RQJHMYQMSA-N captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 claims description 2
• 229940097217 cardiac glycoside Drugs 0.000 claims description 2
• 239000002368 cardiac glycoside Substances 0.000 claims description 2
• 229960000603 cefalotin Drugs 0.000 claims description 2
• 229960004261 cefotaxime Drugs 0.000 claims description 2
• AZZMGZXNTDTSME-JUZDKLSSSA-M cefotaxime sodium Chemical compound [Na+].N([C@@H]1C(N2C(=C(COC(C)=O)CS[C@@H]21)C([O-])=O)=O)C(=O)\C(=N/OC)C1=CSC(N)=N1 AZZMGZXNTDTSME-JUZDKLSSSA-M 0.000 claims description 2
• 229960001991 ceftizoxime Drugs 0.000 claims description 2
• NNULBSISHYWZJU-LLKWHZGFSA-N ceftizoxime Chemical compound N([C@@H]1C(N2C(=CCS[C@@H]21)C(O)=O)=O)C(=O)\C(=N/OC)C1=CSC(N)=N1 NNULBSISHYWZJU-LLKWHZGFSA-N 0.000 claims description 2
• 229940106164 cephalexin Drugs 0.000 claims description 2
• ZAIPMKNFIOOWCQ-UEKVPHQBSA-N cephalexin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C)C(O)=O)=CC=CC=C1 ZAIPMKNFIOOWCQ-UEKVPHQBSA-N 0.000 claims description 2
• 229940124587 cephalosporin Drugs 0.000 claims description 2
• 150000001780 cephalosporins Chemical class 0.000 claims description 2
• VUFGUVLLDPOSBC-XRZFDKQNSA-M cephalothin sodium Chemical compound [Na+].N([C@H]1[C@@H]2N(C1=O)C(=C(CS2)COC(=O)C)C([O-])=O)C(=O)CC1=CC=CS1 VUFGUVLLDPOSBC-XRZFDKQNSA-M 0.000 claims description 2
• 230000002490 cerebral effect Effects 0.000 claims description 2
• 229950008249 chlornaphazine Drugs 0.000 claims description 2
• 235000012000 cholesterol Nutrition 0.000 claims description 2
• 239000000812 cholinergic antagonist Substances 0.000 claims description 2
• GQSGZTBDVNUIQS-DGCLKSJQSA-N ciclonicate Chemical compound C1C(C)(C)C[C@H](C)C[C@H]1OC(=O)C1=CC=CN=C1 GQSGZTBDVNUIQS-DGCLKSJQSA-N 0.000 claims description 2
• 229960003025 ciclonicate Drugs 0.000 claims description 2
• 229960004316 cisplatin Drugs 0.000 claims description 2
• DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims description 2
• 229960004397 cyclophosphamide Drugs 0.000 claims description 2
• 229960000684 cytarabine Drugs 0.000 claims description 2
• KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 claims description 2
• 229960003964 deoxycholic acid Drugs 0.000 claims description 2
• 229960003957 dexamethasone Drugs 0.000 claims description 2
• UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims description 2
• 238000000502 dialysis Methods 0.000 claims description 2
• 229960001259 diclofenac Drugs 0.000 claims description 2
• DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 claims description 2
• 229960005156 digoxin Drugs 0.000 claims description 2
• LTMHDMANZUZIPE-PUGKRICDSA-N digoxin Chemical compound C1[C@H](O)[C@H](O)[C@@H](C)O[C@H]1O[C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3C[C@@H]4[C@]([C@@H]5[C@H]([C@]6(CC[C@@H]([C@@]6(C)[C@H](O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)C[C@@H]2O)C)C[C@@H]1O LTMHDMANZUZIPE-PUGKRICDSA-N 0.000 claims description 2
• LTMHDMANZUZIPE-UHFFFAOYSA-N digoxine Natural products C1C(O)C(O)C(C)OC1OC1C(C)OC(OC2C(OC(OC3CC4C(C5C(C6(CCC(C6(C)C(O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)CC2O)C)CC1O LTMHDMANZUZIPE-UHFFFAOYSA-N 0.000 claims description 2
• 229960002877 dihydralazine Drugs 0.000 claims description 2
• VQKLRVZQQYVIJW-UHFFFAOYSA-N dihydralazine Chemical compound C1=CC=C2C(NN)=NN=C(NN)C2=C1 VQKLRVZQQYVIJW-UHFFFAOYSA-N 0.000 claims description 2
• HESHRHUZIWVEAJ-JGRZULCMSA-N dihydroergotamine Chemical compound C([C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@@](C(N21)=O)(C)NC(=O)[C@H]1CN([C@H]2[C@@H](C3=CC=CC4=NC=C([C]34)C2)C1)C)C1=CC=CC=C1 HESHRHUZIWVEAJ-JGRZULCMSA-N 0.000 claims description 2
• 229960004704 dihydroergotamine Drugs 0.000 claims description 2
• HSUGRBWQSSZJOP-RTWAWAEBSA-N diltiazem Chemical compound C1=CC(OC)=CC=C1[C@H]1[C@@H](OC(C)=O)C(=O)N(CCN(C)C)C2=CC=CC=C2S1 HSUGRBWQSSZJOP-RTWAWAEBSA-N 0.000 claims description 2
• 229960004166 diltiazem Drugs 0.000 claims description 2
• RXPRRQLKFXBCSJ-UHFFFAOYSA-N dl-Vincamin Natural products C1=CC=C2C(CCN3CCC4)=C5C3C4(CC)CC(O)(C(=O)OC)N5C2=C1 RXPRRQLKFXBCSJ-UHFFFAOYSA-N 0.000 claims description 2
• 229960004679 doxorubicin Drugs 0.000 claims description 2
• 229950007402 eltanolone Drugs 0.000 claims description 2
• 229960000873 enalapril Drugs 0.000 claims description 2
• GBXSMTUPTTWBMN-XIRDDKMYSA-N enalapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)CC1=CC=CC=C1 GBXSMTUPTTWBMN-XIRDDKMYSA-N 0.000 claims description 2
• 229960002029 endralazine Drugs 0.000 claims description 2
• ALAXZYHFVBSJKZ-UHFFFAOYSA-N endralazine Chemical compound C1CC=2N=NC(NN)=CC=2CN1C(=O)C1=CC=CC=C1 ALAXZYHFVBSJKZ-UHFFFAOYSA-N 0.000 claims description 2
• 229950009110 etisazole Drugs 0.000 claims description 2
• 238000001704 evaporation Methods 0.000 claims description 2
• 230000008020 evaporation Effects 0.000 claims description 2
• 229960003528 flurazepam Drugs 0.000 claims description 2
• SAADBVWGJQAEFS-UHFFFAOYSA-N flurazepam Chemical compound N=1CC(=O)N(CCN(CC)CC)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1F SAADBVWGJQAEFS-UHFFFAOYSA-N 0.000 claims description 2
• 229960000308 fosfomycin Drugs 0.000 claims description 2
• YMDXZJFXQJVXBF-STHAYSLISA-N fosfomycin Chemical compound C[C@@H]1O[C@@H]1P(O)(O)=O YMDXZJFXQJVXBF-STHAYSLISA-N 0.000 claims description 2
• GJXWDTUCERCKIX-UHFFFAOYSA-N fosmidomycin Chemical compound O=CN(O)CCCP(O)(O)=O GJXWDTUCERCKIX-UHFFFAOYSA-N 0.000 claims description 2
• 229950006501 fosmidomycin Drugs 0.000 claims description 2
• 239000008273 gelatin Substances 0.000 claims description 2
• 229920000159 gelatin Polymers 0.000 claims description 2
• 235000019322 gelatine Nutrition 0.000 claims description 2
• 235000011852 gelatine desserts Nutrition 0.000 claims description 2
• 150000002339 glycosphingolipids Chemical class 0.000 claims description 2
• DDUHZTYCFQRHIY-RBHXEPJQSA-N griseofulvin Chemical compound COC1=CC(=O)C[C@@H](C)[C@@]11C(=O)C(C(OC)=CC(OC)=C2Cl)=C2O1 DDUHZTYCFQRHIY-RBHXEPJQSA-N 0.000 claims description 2
• 229960002867 griseofulvin Drugs 0.000 claims description 2
• KRQAMFQCSAJCRH-UHFFFAOYSA-N hexobendine Chemical compound COC1=C(OC)C(OC)=CC(C(=O)OCCCN(C)CCN(C)CCCOC(=O)C=2C=C(OC)C(OC)=C(OC)C=2)=C1 KRQAMFQCSAJCRH-UHFFFAOYSA-N 0.000 claims description 2
• 229960002212 hexobendine Drugs 0.000 claims description 2
• 229960002474 hydralazine Drugs 0.000 claims description 2
• 229960000890 hydrocortisone Drugs 0.000 claims description 2
• 239000005555 hypertensive agent Substances 0.000 claims description 2
• 239000003326 hypnotic agent Substances 0.000 claims description 2
• 230000000147 hypnotic effect Effects 0.000 claims description 2
• 102000018358 immunoglobulin Human genes 0.000 claims description 2
• 229940072221 immunoglobulins Drugs 0.000 claims description 2
• 229960000905 indomethacin Drugs 0.000 claims description 2
• 229960001361 ipratropium bromide Drugs 0.000 claims description 2
• KEWHKYJURDBRMN-ZEODDXGYSA-M ipratropium bromide hydrate Chemical compound O.[Br-].O([C@H]1C[C@H]2CC[C@@H](C1)[N@@+]2(C)C(C)C)C(=O)C(CO)C1=CC=CC=C1 KEWHKYJURDBRMN-ZEODDXGYSA-M 0.000 claims description 2
• 229960004125 ketoconazole Drugs 0.000 claims description 2
• DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 claims description 2
• 229960000991 ketoprofen Drugs 0.000 claims description 2
• 229960001632 labetalol Drugs 0.000 claims description 2
• 229960004391 lorazepam Drugs 0.000 claims description 2
• 229960004961 mechlorethamine Drugs 0.000 claims description 2
• HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical compound ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 claims description 2
• 229960003746 metildigoxin Drugs 0.000 claims description 2
• IYJMSDVSVHDVGT-PEQKVOOWSA-N metildigoxin Chemical compound O1[C@H](C)[C@@H](OC)[C@@H](O)C[C@@H]1O[C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3C[C@@H]4[C@]([C@@H]5[C@H]([C@]6(CC[C@@H]([C@@]6(C)[C@H](O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)C[C@@H]2O)C)C[C@@H]1O IYJMSDVSVHDVGT-PEQKVOOWSA-N 0.000 claims description 2
• IUBSYMUCCVWXPE-UHFFFAOYSA-N metoprolol Chemical compound COCCC1=CC=C(OCC(O)CNC(C)C)C=C1 IUBSYMUCCVWXPE-UHFFFAOYSA-N 0.000 claims description 2
• 229960002237 metoprolol Drugs 0.000 claims description 2
• 229960003632 minoxidil Drugs 0.000 claims description 2
• 229960004857 mitomycin Drugs 0.000 claims description 2
• 229960004027 molsidomine Drugs 0.000 claims description 2
• XLFWDASMENKTKL-UHFFFAOYSA-N molsidomine Chemical compound O1C(N=C([O-])OCC)=C[N+](N2CCOCC2)=N1 XLFWDASMENKTKL-UHFFFAOYSA-N 0.000 claims description 2
• MYCMTMIGRXJNSO-UHFFFAOYSA-N moxaverine Chemical compound N=1C(CC)=CC2=CC(OC)=C(OC)C=C2C=1CC1=CC=CC=C1 MYCMTMIGRXJNSO-UHFFFAOYSA-N 0.000 claims description 2
• 229960002902 moxaverine Drugs 0.000 claims description 2
• CPYSWRYVSINXMC-UHFFFAOYSA-N n-ethyl-1,2-benzothiazol-3-amine Chemical compound C1=CC=C2C(NCC)=NSC2=C1 CPYSWRYVSINXMC-UHFFFAOYSA-N 0.000 claims description 2
• HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 claims description 2
• 229960001597 nifedipine Drugs 0.000 claims description 2
• 229960000715 nimodipine Drugs 0.000 claims description 2
• KJONHKAYOJNZEC-UHFFFAOYSA-N nitrazepam Chemical compound C12=CC([N+](=O)[O-])=CC=C2NC(=O)CN=C1C1=CC=CC=C1 KJONHKAYOJNZEC-UHFFFAOYSA-N 0.000 claims description 2
• 229960001454 nitrazepam Drugs 0.000 claims description 2
• 229960005425 nitrendipine Drugs 0.000 claims description 2
• 229960002035 penbutolol Drugs 0.000 claims description 2
• KQXKVJAGOJTNJS-HNNXBMFYSA-N penbutolol Chemical compound CC(C)(C)NC[C@H](O)COC1=CC=CC=C1C1CCCC1 KQXKVJAGOJTNJS-HNNXBMFYSA-N 0.000 claims description 2
• RLLPVAHGXHCWKJ-UHFFFAOYSA-N permethrin Chemical compound CC1(C)C(C=C(Cl)Cl)C1C(=O)OCC1=CC=CC(OC=2C=CC=CC=2)=C1 RLLPVAHGXHCWKJ-UHFFFAOYSA-N 0.000 claims description 2
• 229960000490 permethrin Drugs 0.000 claims description 2
• 229960002508 pindolol Drugs 0.000 claims description 2
• JZQKKSLKJUAGIC-UHFFFAOYSA-N pindolol Chemical compound CC(C)NCC(O)COC1=CC=CC2=C1C=CN2 JZQKKSLKJUAGIC-UHFFFAOYSA-N 0.000 claims description 2
• PIDSZXPFGCURGN-UHFFFAOYSA-N pirprofen Chemical compound ClC1=CC(C(C(O)=O)C)=CC=C1N1CC=CC1 PIDSZXPFGCURGN-UHFFFAOYSA-N 0.000 claims description 2
• 229960000851 pirprofen Drugs 0.000 claims description 2
• 229920000570 polyether Polymers 0.000 claims description 2
• 229920001451 polypropylene glycol Polymers 0.000 claims description 2
• 229960004618 prednisone Drugs 0.000 claims description 2
• XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 claims description 2
• MVFGUOIZUNYYSO-UHFFFAOYSA-N prilocaine Chemical compound CCCNC(C)C(=O)NC1=CC=CC=C1C MVFGUOIZUNYYSO-UHFFFAOYSA-N 0.000 claims description 2
• 229960001807 prilocaine Drugs 0.000 claims description 2
• 229960003387 progesterone Drugs 0.000 claims description 2
• 239000000186 progesterone Substances 0.000 claims description 2
• YZZCJYJBCUJISI-UHFFFAOYSA-N propatylnitrate Chemical compound [O-][N+](=O)OCC(CC)(CO[N+]([O-])=O)CO[N+]([O-])=O YZZCJYJBCUJISI-UHFFFAOYSA-N 0.000 claims description 2
• 229960003402 propatylnitrate Drugs 0.000 claims description 2
• 229960003712 propranolol Drugs 0.000 claims description 2
• 229940001470 psychoactive drug Drugs 0.000 claims description 2
• 239000004089 psychotropic agent Substances 0.000 claims description 2
• WDZCUPBHRAEYDL-GZAUEHORSA-N rifapentine Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC=2C(O)=C3C(O)=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N(CC1)CCN1C1CCCC1 WDZCUPBHRAEYDL-GZAUEHORSA-N 0.000 claims description 2
• 229960002599 rifapentine Drugs 0.000 claims description 2
• 229920006395 saturated elastomer Polymers 0.000 claims description 2
• 150000004671 saturated fatty acids Chemical class 0.000 claims description 2
• 235000003441 saturated fatty acids Nutrition 0.000 claims description 2
• 229960000230 sobrerol Drugs 0.000 claims description 2
• NRHMKIHPTBHXPF-TUJRSCDTSA-M sodium cholate Chemical compound [Na+].C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 NRHMKIHPTBHXPF-TUJRSCDTSA-M 0.000 claims description 2
• JAJWGJBVLPIOOH-IZYKLYLVSA-M sodium taurocholate Chemical compound [Na+].C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCS([O-])(=O)=O)C)[C@@]2(C)[C@@H](O)C1 JAJWGJBVLPIOOH-IZYKLYLVSA-M 0.000 claims description 2
• FKJIJBSJQSMPTI-CAOXKPNISA-M sodium;(4r)-4-[(5s,8r,9s,10s,13r,14s,17r)-10,13-dimethyl-3,7,12-trioxo-1,2,4,5,6,8,9,11,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-17-yl]pentanoate Chemical compound [Na+].C1CC(=O)C[C@H]2CC(=O)[C@H]3[C@@H]4CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]4(C)C(=O)C[C@@H]3[C@]21C FKJIJBSJQSMPTI-CAOXKPNISA-M 0.000 claims description 2
• 150000003408 sphingolipids Chemical class 0.000 claims description 2
• 238000011146 sterile filtration Methods 0.000 claims description 2
• 229930002534 steroid glycoside Natural products 0.000 claims description 2
• 239000003270 steroid hormone Substances 0.000 claims description 2
• 150000008143 steroidal glycosides Chemical class 0.000 claims description 2
• 229960003967 suloctidil Drugs 0.000 claims description 2
• 230000009885 systemic effect Effects 0.000 claims description 2
• 229960003410 testosterone decanoate Drugs 0.000 claims description 2
• 229960000746 testosterone undecanoate Drugs 0.000 claims description 2
• UDSFVOAUHKGBEK-CNQKSJKFSA-N testosterone undecanoate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](OC(=O)CCCCCCCCCC)[C@@]1(C)CC2 UDSFVOAUHKGBEK-CNQKSJKFSA-N 0.000 claims description 2
• 230000001225 therapeutic effect Effects 0.000 claims description 2
• OMDMTHRBGUBUCO-UHFFFAOYSA-N trans-sobrerol Natural products CC1=CCC(C(C)(C)O)CC1O OMDMTHRBGUBUCO-UHFFFAOYSA-N 0.000 claims description 2
• 229960002431 trimipramine Drugs 0.000 claims description 2
• ZSCDBOWYZJWBIY-UHFFFAOYSA-N trimipramine Chemical compound C1CC2=CC=CC=C2N(CC(CN(C)C)C)C2=CC=CC=C21 ZSCDBOWYZJWBIY-UHFFFAOYSA-N 0.000 claims description 2
• 229960001722 verapamil Drugs 0.000 claims description 2
• 229960003636 vidarabine Drugs 0.000 claims description 2
• 229960002726 vincamine Drugs 0.000 claims description 2
• 229960004528 vincristine Drugs 0.000 claims description 2
• OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 claims description 2
• OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 claims description 2
• 229940088594 vitamin Drugs 0.000 claims description 2
• 229930003231 vitamin Natural products 0.000 claims description 2
• 235000013343 vitamin Nutrition 0.000 claims description 2
• 239000011782 vitamin Substances 0.000 claims description 2
• 239000011710 vitamin D Substances 0.000 claims description 2
• 235000019166 vitamin D Nutrition 0.000 claims description 2
• 235000019165 vitamin E Nutrition 0.000 claims description 2
• 239000011709 vitamin E Substances 0.000 claims description 2
• 239000011712 vitamin K Substances 0.000 claims description 2
• 235000019168 vitamin K Nutrition 0.000 claims description 2
• 229940041603 vitamin k 3 Drugs 0.000 claims description 2
• IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims 4
• YNBADRVTZLEFNH-UHFFFAOYSA-N methyl nicotinate Chemical compound COC(=O)C1=CC=CN=C1 YNBADRVTZLEFNH-UHFFFAOYSA-N 0.000 claims 4
• DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims 3
• 150000008163 sugars Chemical class 0.000 claims 3
• 229960001238 methylnicotinate Drugs 0.000 claims 2
• 229940125723 sedative agent Drugs 0.000 claims 2
• 239000000932 sedative agent Substances 0.000 claims 2
• OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 claims 1
• GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 claims 1
• 229910002651 NO3 Inorganic materials 0.000 claims 1
• NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 claims 1
• 241000700605 Viruses Species 0.000 claims 1
• MSCMJGNDXDIFNR-UHFFFAOYSA-N [ClH]1N=NC=C1 Chemical compound [ClH]1N=NC=C1 MSCMJGNDXDIFNR-UHFFFAOYSA-N 0.000 claims 1
• 229960003304 acetyldigoxin Drugs 0.000 claims 1
• HWKJSYYYURVNQU-DXJNJSHLSA-N acetyldigoxin Chemical compound C1[C@H](OC(C)=O)[C@H](O)[C@@H](C)O[C@H]1O[C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3C[C@@H]4[C@]([C@@H]5[C@H]([C@]6(CC[C@@H]([C@@]6(C)[C@H](O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)C[C@@H]2O)C)C[C@@H]1O HWKJSYYYURVNQU-DXJNJSHLSA-N 0.000 claims 1
• MGVYFNHJWXJYBE-UHFFFAOYSA-N alpha-Acetyl-digoxin Natural products CC1OC(CC(O)C1O)OC2C(O)CC(OC3C(C)OC(CC3OC(=O)C)OC4CCC5(C)C(CCC6C5CCC7(C)C(C(O)CC67O)C8=CC(=O)OC8)C4)OC2C MGVYFNHJWXJYBE-UHFFFAOYSA-N 0.000 claims 1
• GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 claims 1
• DKRSEIPLAZTSFD-UHFFFAOYSA-N d-quinotoxine Natural products C12=CC(OC)=CC=C2N=CC=C1C(=O)CCC1CCNCC1C=C DKRSEIPLAZTSFD-UHFFFAOYSA-N 0.000 claims 1
• 210000000936 intestine Anatomy 0.000 claims 1
• DKRSEIPLAZTSFD-LSDHHAIUSA-N viquidil Chemical compound C12=CC(OC)=CC=C2N=CC=C1C(=O)CC[C@@H]1CCNC[C@@H]1C=C DKRSEIPLAZTSFD-LSDHHAIUSA-N 0.000 claims 1
• 229960003353 viquidil Drugs 0.000 claims 1
• 239000008346 aqueous phase Substances 0.000 abstract description 41
• 239000011159 matrix material Substances 0.000 abstract description 39
• 239000002537 cosmetic Substances 0.000 abstract description 6
• 235000013305 food Nutrition 0.000 abstract description 4
• 238000007911 parenteral administration Methods 0.000 abstract description 4
• 239000013543 active substance Substances 0.000 abstract description 3
• 238000002156 mixing Methods 0.000 abstract description 3
• 229960005486 vaccine Drugs 0.000 abstract description 2
• 239000002552 dosage form Substances 0.000 abstract 1
• PVNIQBQSYATKKL-UHFFFAOYSA-N tripalmitin Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCC PVNIQBQSYATKKL-UHFFFAOYSA-N 0.000 description 110
• 239000000523 sample Substances 0.000 description 66
• RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 40
• 229960004906 thiomersal Drugs 0.000 description 40
• 239000000155 melt Substances 0.000 description 33
• IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical class CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 30
• 239000000787 lecithin Substances 0.000 description 28
• 229940067606 lecithin Drugs 0.000 description 28
• 235000010445 lecithin Nutrition 0.000 description 28
• 238000003860 storage Methods 0.000 description 28
• 238000002296 dynamic light scattering Methods 0.000 description 26
• 239000012154 double-distilled water Substances 0.000 description 24
• 238000009826 distribution Methods 0.000 description 22
• 230000000694 effects Effects 0.000 description 20
• 239000002960 lipid emulsion Substances 0.000 description 20
• JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 description 18
• 238000004090 dissolution Methods 0.000 description 18
• 229940083466 soybean lecithin Drugs 0.000 description 18
• 230000006641 stabilisation Effects 0.000 description 16
• 238000011105 stabilization Methods 0.000 description 16
• 238000009472 formulation Methods 0.000 description 13
• 239000012876 carrier material Substances 0.000 description 12
• 230000007774 longterm Effects 0.000 description 12
• 239000003995 emulsifying agent Substances 0.000 description 11
• 229940116364 hard fat Drugs 0.000 description 11
• 238000005755 formation reaction Methods 0.000 description 10
• 239000000243 solution Substances 0.000 description 10
• 210000000865 mononuclear phagocyte system Anatomy 0.000 description 9
• 239000000843 powder Substances 0.000 description 9
• 238000003756 stirring Methods 0.000 description 9
• 230000007423 decrease Effects 0.000 description 8
• 239000003937 drug carrier Substances 0.000 description 8
• 239000003925 fat Substances 0.000 description 8
• 239000000499 gel Substances 0.000 description 8
• 238000001990 intravenous administration Methods 0.000 description 8
• 230000008685 targeting Effects 0.000 description 8
• 239000000470 constituent Substances 0.000 description 7
• 238000002050 diffraction method Methods 0.000 description 7
• 238000009792 diffusion process Methods 0.000 description 7
• 230000002209 hydrophobic effect Effects 0.000 description 7
• 239000002502 liposome Substances 0.000 description 7
• 230000009467 reduction Effects 0.000 description 7
• RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 6
• 238000003917 TEM image Methods 0.000 description 6
• 230000002776 aggregation Effects 0.000 description 6
• 238000004220 aggregation Methods 0.000 description 6
• 210000004369 blood Anatomy 0.000 description 6
• 239000008280 blood Substances 0.000 description 6
• 230000002500 effect on skin Effects 0.000 description 6
• 238000005259 measurement Methods 0.000 description 6
• 239000002105 nanoparticle Substances 0.000 description 6
• 229920001983 poloxamer Polymers 0.000 description 6
• 229920001992 poloxamer 407 Polymers 0.000 description 6
• 229920001485 poly(butyl acrylate) polymer Polymers 0.000 description 6
• 230000002685 pulmonary effect Effects 0.000 description 6
• 231100000331 toxic Toxicity 0.000 description 6
• 230000002588 toxic effect Effects 0.000 description 6
• 230000036760 body temperature Effects 0.000 description 5
• 230000015556 catabolic process Effects 0.000 description 5
• 210000004027 cell Anatomy 0.000 description 5
• 239000007957 coemulsifier Substances 0.000 description 5
• 238000010348 incorporation Methods 0.000 description 5
• 239000011859 microparticle Substances 0.000 description 5
• 239000004005 microsphere Substances 0.000 description 5
• 230000001105 regulatory effect Effects 0.000 description 5
• 238000002604 ultrasonography Methods 0.000 description 5
• 230000009471 action Effects 0.000 description 4
• 230000008859 change Effects 0.000 description 4
• 238000005345 coagulation Methods 0.000 description 4
• 230000015271 coagulation Effects 0.000 description 4
• 238000013270 controlled release Methods 0.000 description 4
• 238000002425 crystallisation Methods 0.000 description 4
• 230000008025 crystallization Effects 0.000 description 4
• 238000000227 grinding Methods 0.000 description 4
• 230000007246 mechanism Effects 0.000 description 4
• 239000003921 oil Substances 0.000 description 4
• 235000019198 oils Nutrition 0.000 description 4
• 239000003960 organic solvent Substances 0.000 description 4
• 229960000502 poloxamer Drugs 0.000 description 4
• 239000002904 solvent Substances 0.000 description 4
• 238000001179 sorption measurement Methods 0.000 description 4
• 239000012798 spherical particle Substances 0.000 description 4
• 230000000087 stabilizing effect Effects 0.000 description 4
• 230000007704 transition Effects 0.000 description 4
• 238000003260 vortexing Methods 0.000 description 4
• 238000004736 wide-angle X-ray diffraction Methods 0.000 description 4
• 206010015866 Extravasation Diseases 0.000 description 3
• WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
• 239000007864 aqueous solution Substances 0.000 description 3
• 230000008901 benefit Effects 0.000 description 3
• 210000001185 bone marrow Anatomy 0.000 description 3
• 229910052799 carbon Inorganic materials 0.000 description 3
• 238000006731 degradation reaction Methods 0.000 description 3
• 239000012153 distilled water Substances 0.000 description 3
• 230000003511 endothelial effect Effects 0.000 description 3
• 230000036251 extravasation Effects 0.000 description 3
• 239000000417 fungicide Substances 0.000 description 3
• 230000005660 hydrophilic surface Effects 0.000 description 3
• 239000012535 impurity Substances 0.000 description 3
• 239000000178 monomer Substances 0.000 description 3
• 235000016236 parenteral nutrition Nutrition 0.000 description 3
• 229920001993 poloxamer 188 Polymers 0.000 description 3
• 229920001987 poloxamine Polymers 0.000 description 3
• 239000002994 raw material Substances 0.000 description 3
• 239000013049 sediment Substances 0.000 description 3
• 238000001757 thermogravimetry curve Methods 0.000 description 3
• 230000002110 toxicologic effect Effects 0.000 description 3
• 231100000027 toxicology Toxicity 0.000 description 3
• 230000009466 transformation Effects 0.000 description 3
• IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
• OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
• HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
• 208000005189 Embolism Diseases 0.000 description 2
• ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
• 229920002359 Tetronic® Polymers 0.000 description 2
• FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 2
• 239000002253 acid Substances 0.000 description 2
• 239000002246 antineoplastic agent Substances 0.000 description 2
• 239000012736 aqueous medium Substances 0.000 description 2
• 239000012620 biological material Substances 0.000 description 2
• 150000001720 carbohydrates Chemical class 0.000 description 2
• 230000003293 cardioprotective effect Effects 0.000 description 2
• 238000004581 coalescence Methods 0.000 description 2
• 239000000084 colloidal system Substances 0.000 description 2
• 239000012059 conventional drug carrier Substances 0.000 description 2
• 238000012864 cross contamination Methods 0.000 description 2
• 230000001419 dependent effect Effects 0.000 description 2
• 238000000113 differential scanning calorimetry Methods 0.000 description 2
• 238000012377 drug delivery Methods 0.000 description 2
• 239000000428 dust Substances 0.000 description 2
• HQPMKSGTIOYHJT-UHFFFAOYSA-N ethane-1,2-diol;propane-1,2-diol Chemical compound OCCO.CC(O)CO HQPMKSGTIOYHJT-UHFFFAOYSA-N 0.000 description 2
• 230000001747 exhibiting effect Effects 0.000 description 2
• 238000004880 explosion Methods 0.000 description 2
• 239000003337 fertilizer Substances 0.000 description 2
• 239000011521 glass Substances 0.000 description 2
• 125000005456 glyceride group Chemical group 0.000 description 2
• 229960005150 glycerol Drugs 0.000 description 2
• 239000004519 grease Substances 0.000 description 2
• 230000003301 hydrolyzing effect Effects 0.000 description 2
• 238000001727 in vivo Methods 0.000 description 2
• 238000002347 injection Methods 0.000 description 2
• 239000007924 injection Substances 0.000 description 2
• 239000012907 medicinal substance Substances 0.000 description 2
• 229910052751 metal Inorganic materials 0.000 description 2
• 239000002184 metal Substances 0.000 description 2
• 231100000956 nontoxicity Toxicity 0.000 description 2
• 230000006911 nucleation Effects 0.000 description 2
• 238000010899 nucleation Methods 0.000 description 2
• 238000012856 packing Methods 0.000 description 2
• 238000005191 phase separation Methods 0.000 description 2
• 238000001907 polarising light microscopy Methods 0.000 description 2
• 229940044476 poloxamer 407 Drugs 0.000 description 2
• 238000001694 spray drying Methods 0.000 description 2
• 238000010561 standard procedure Methods 0.000 description 2
• 238000013268 sustained release Methods 0.000 description 2
• 239000012730 sustained-release form Substances 0.000 description 2
• 230000005469 synchrotron radiation Effects 0.000 description 2
• 231100000419 toxicity Toxicity 0.000 description 2
• 230000001988 toxicity Effects 0.000 description 2
• 238000000844 transformation Methods 0.000 description 2
• 230000032258 transport Effects 0.000 description 2
• 229960001947 tripalmitin Drugs 0.000 description 2
• 229940045997 vitamin a Drugs 0.000 description 2
• FLPJVCMIKUWSDR-UHFFFAOYSA-N 2-(4-formylphenoxy)acetamide Chemical compound NC(=O)COC1=CC=C(C=O)C=C1 FLPJVCMIKUWSDR-UHFFFAOYSA-N 0.000 description 1
• YEYKMVJDLWJFOA-UHFFFAOYSA-N 2-propoxyethanol Chemical compound CCCOCCO YEYKMVJDLWJFOA-UHFFFAOYSA-N 0.000 description 1
• DZVPGIORVGSQMC-UHFFFAOYSA-N 3,5-dichloro-2,4-dimethoxy-6-(trichloromethyl)pyridine Chemical compound COC1=NC(C(Cl)(Cl)Cl)=C(Cl)C(OC)=C1Cl DZVPGIORVGSQMC-UHFFFAOYSA-N 0.000 description 1
• ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 description 1
• 108090000790 Enzymes Proteins 0.000 description 1
• 102000004190 Enzymes Human genes 0.000 description 1
• 244000068988 Glycine max Species 0.000 description 1
• 235000010469 Glycine max Nutrition 0.000 description 1
• 108010007979 Glycocholic Acid Proteins 0.000 description 1
• 229920002274 Nalgene Polymers 0.000 description 1
• PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
• 238000001016 Ostwald ripening Methods 0.000 description 1
• 206010057249 Phagocytosis Diseases 0.000 description 1
• 238000002441 X-ray diffraction Methods 0.000 description 1
• 238000009825 accumulation Methods 0.000 description 1
• 239000011149 active material Substances 0.000 description 1
• 235000019169 all-trans-retinol Nutrition 0.000 description 1
• 239000011717 all-trans-retinol Substances 0.000 description 1
• 229910052782 aluminium Inorganic materials 0.000 description 1
• XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
• 229940041181 antineoplastic drug Drugs 0.000 description 1
• 239000002249 anxiolytic agent Substances 0.000 description 1
• 238000013459 approach Methods 0.000 description 1
• 239000007900 aqueous suspension Substances 0.000 description 1
• 230000002902 bimodal effect Effects 0.000 description 1
• 229960000074 biopharmaceutical Drugs 0.000 description 1
• 210000001124 body fluid Anatomy 0.000 description 1
• 239000010839 body fluid Substances 0.000 description 1
• 239000006172 buffering agent Substances 0.000 description 1
• 239000002775 capsule Substances 0.000 description 1
• 235000014633 carbohydrates Nutrition 0.000 description 1
• 239000000969 carrier Substances 0.000 description 1
• 239000007765 cera alba Substances 0.000 description 1
• 229940074979 cetyl palmitate Drugs 0.000 description 1
• 150000008280 chlorinated hydrocarbons Chemical class 0.000 description 1
• 239000011248 coating agent Substances 0.000 description 1
• 238000000576 coating method Methods 0.000 description 1
• 235000017471 coenzyme Q10 Nutrition 0.000 description 1
• ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 description 1
• 238000011109 contamination Methods 0.000 description 1
• 230000001276 controlling effect Effects 0.000 description 1
• 238000007796 conventional method Methods 0.000 description 1
• 239000006071 cream Substances 0.000 description 1
• 239000003431 cross linking reagent Substances 0.000 description 1
• 230000003111 delayed effect Effects 0.000 description 1
• 238000002716 delivery method Methods 0.000 description 1
• 238000001514 detection method Methods 0.000 description 1
• 238000011161 development Methods 0.000 description 1
• 229940088679 drug related substance Drugs 0.000 description 1
• 238000007720 emulsion polymerization reaction Methods 0.000 description 1
• 238000001125 extrusion Methods 0.000 description 1
• SMANXXCATUTDDT-QPJJXVBHSA-N flunarizine Chemical compound C1=CC(F)=CC=C1C(C=1C=CC(F)=CC=1)N1CCN(C\C=C\C=2C=CC=CC=2)CC1 SMANXXCATUTDDT-QPJJXVBHSA-N 0.000 description 1
• 229960000326 flunarizine Drugs 0.000 description 1
• 230000008014 freezing Effects 0.000 description 1
• 238000007710 freezing Methods 0.000 description 1
• 230000036541 health Effects 0.000 description 1
• PXDJXZJSCPSGGI-UHFFFAOYSA-N hexadecanoic acid hexadecyl ester Natural products CCCCCCCCCCCCCCCCOC(=O)CCCCCCCCCCCCCCC PXDJXZJSCPSGGI-UHFFFAOYSA-N 0.000 description 1
• 230000005847 immunogenicity Effects 0.000 description 1
• 238000011534 incubation Methods 0.000 description 1
• 239000003978 infusion fluid Substances 0.000 description 1
• 230000016507 interphase Effects 0.000 description 1
• 230000031891 intestinal absorption Effects 0.000 description 1
• 210000004347 intestinal mucosa Anatomy 0.000 description 1
• 229940028435 intralipid Drugs 0.000 description 1
• 238000011835 investigation Methods 0.000 description 1
• 230000002366 lipolytic effect Effects 0.000 description 1
• 239000004973 liquid crystal related substance Substances 0.000 description 1
• 210000004185 liver Anatomy 0.000 description 1
• 238000011068 loading method Methods 0.000 description 1
• 238000004599 local-density approximation Methods 0.000 description 1
• 210000002751 lymph Anatomy 0.000 description 1
• 238000003760 magnetic stirring Methods 0.000 description 1
• 230000001404 mediated effect Effects 0.000 description 1
• 239000003094 microcapsule Substances 0.000 description 1
• 238000012544 monitoring process Methods 0.000 description 1
• 235000001968 nicotinic acid Nutrition 0.000 description 1
• 239000011664 nicotinic acid Substances 0.000 description 1
• 229910052757 nitrogen Inorganic materials 0.000 description 1
• 231100000252 nontoxic Toxicity 0.000 description 1
• 230000003000 nontoxic effect Effects 0.000 description 1
• 239000007764 o/w emulsion Substances 0.000 description 1
• 239000008188 pellet Substances 0.000 description 1
• 230000008782 phagocytosis Effects 0.000 description 1
• 239000008194 pharmaceutical composition Substances 0.000 description 1
• 238000010587 phase diagram Methods 0.000 description 1
• 230000005502 phase rule Effects 0.000 description 1
• 230000008884 pinocytosis Effects 0.000 description 1
• BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 1
• 231100000614 poison Toxicity 0.000 description 1
• 229920000771 poly (alkylcyanoacrylate) Polymers 0.000 description 1
• 229920000747 poly(lactic acid) Polymers 0.000 description 1
• 239000004626 polylactic acid Substances 0.000 description 1
• 229920006254 polymer film Polymers 0.000 description 1
• 239000002243 precursor Substances 0.000 description 1
• 230000002335 preservative effect Effects 0.000 description 1
• 239000001294 propane Substances 0.000 description 1
• 239000011251 protective drug Substances 0.000 description 1
• 102000005962 receptors Human genes 0.000 description 1
• 108020003175 receptors Proteins 0.000 description 1
• 230000000717 retained effect Effects 0.000 description 1
• 238000004062 sedimentation Methods 0.000 description 1
• 210000002966 serum Anatomy 0.000 description 1
• 238000005549 size reduction Methods 0.000 description 1
• 238000004513 sizing Methods 0.000 description 1
• 235000002316 solid fats Nutrition 0.000 description 1
• 239000008247 solid mixture Substances 0.000 description 1
• 239000007790 solid phase Substances 0.000 description 1
• 238000007711 solidification Methods 0.000 description 1
• 230000008023 solidification Effects 0.000 description 1
• 230000003381 solubilizing effect Effects 0.000 description 1
• 238000000935 solvent evaporation Methods 0.000 description 1
• 238000000527 sonication Methods 0.000 description 1
• 235000012424 soybean oil Nutrition 0.000 description 1
• 239000003549 soybean oil Substances 0.000 description 1
• 239000004045 soybean oil emulsion Substances 0.000 description 1
• 210000000952 spleen Anatomy 0.000 description 1
• 239000007921 spray Substances 0.000 description 1
• 230000001954 sterilising effect Effects 0.000 description 1
• 238000004659 sterilization and disinfection Methods 0.000 description 1
• 210000002784 stomach Anatomy 0.000 description 1
• 238000006467 substitution reaction Methods 0.000 description 1
• 238000013269 sustained drug release Methods 0.000 description 1
• 239000003826 tablet Substances 0.000 description 1
• 229960003604 testosterone Drugs 0.000 description 1
• 231100001274 therapeutic index Toxicity 0.000 description 1
• 210000001519 tissue Anatomy 0.000 description 1
• 239000003440 toxic substance Substances 0.000 description 1
• 238000012546 transfer Methods 0.000 description 1
• UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
• DUXYWXYOBMKGIN-UHFFFAOYSA-N trimyristin Chemical compound CCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCC DUXYWXYOBMKGIN-UHFFFAOYSA-N 0.000 description 1
• 229960004747 ubidecarenone Drugs 0.000 description 1
• 239000008215 water for injection Substances 0.000 description 1